Literature DB >> 10874685

Heterogeneity of delta-aminolevulinic acid-induced protoporphyrin IX fluorescence in human glioma cells and leukemic lymphocytes.

S Eléouet1, N Rousset, J Carré, V Vonarx, C Vilatte, C Louët, Y Lajat, T Patrice.   

Abstract

Delta-aminolevulinic acid (ALA)-PDT efficacy is particularly dependent on the quality of protoporphyrin IX (PpIX)-induced synthesis. The purpose of this study was to determine the ability of cells from two human cancer types to synthesise PpIX after ALA administration. Biopsies of glioma cells have been obtained from patients with glioblastomas that have or have not been given ALA IV (ex vivo incubation). Peripheral blood lymphocytes, obtained from leukemic patients, have also been ALA-incubated in vitro. In glioma cells, fluorescence heterogeneity was extensive either in ALA infused patients or in ex vivo ALA incubated cells. Mean intensities after 3 h were 110 cts (range 0-340) and 1000 cts (range 0-3600). Similar results were found in leukemic lymphocytes where cell fluorescence varied from 0 to 480 cts with a percentage of fluorescent cells varying with time and from one patient to another. Furthermore, PpIX was not detectable in two patients with CLL. These observations suggest that a marked heterogeneity of ALA uptake and/or PpIX synthesis exists in a given human cancer cell population particularly after systemic administration. Improvements for ALA transformation into PpIX are strongly recommended to ensure the efficacy of ALA/PpIX-PDT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10874685     DOI: 10.1080/01616412.2000.11740685

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  7 in total

1.  Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme.

Authors:  Tiara S Napier; Neha Udayakumar; Aditi H Jani; Yolanda E Hartman; Hailey A Houson; Lindsay Moore; Hope M Amm; Nynke S van den Berg; Anna G Sorace; Jason M Warram
Journal:  Mol Cancer Ther       Date:  2020-06-30       Impact factor: 6.261

2.  Anticancer drug released from near IR-activated prodrug overcomes spatiotemporal limits of singlet oxygen.

Authors:  Pallavi Rajaputra; Moses Bio; Gregory Nkepang; Pritam Thapa; Sukyung Woo; Youngjae You
Journal:  Bioorg Med Chem       Date:  2016-02-21       Impact factor: 3.641

3.  Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX.

Authors:  Frank Duffner; Rainer Ritz; Dirk Freudenstein; Michael Weller; Klaus Dietz; Johannes Wessels
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

4.  Noninvasive measurement of aminolevulinic acid-induced protoporphyrin IX fluorescence allowing detection of murine glioma in vivo.

Authors:  Summer L Gibbs-Strauss; Julia A O'Hara; P Jack Hoopes; Tayyaba Hasan; Brian W Pogue
Journal:  J Biomed Opt       Date:  2009 Jan-Feb       Impact factor: 3.170

5.  Induction of immune mediators in glioma and prostate cancer cells by non-lethal photodynamic therapy.

Authors:  Robert Kammerer; Alexander Buchner; Patrick Palluch; Thomas Pongratz; Konstantin Oboukhovskij; Wolfgang Beyer; Ann Johansson; Herbert Stepp; Reinhold Baumgartner; Wolfgang Zimmermann
Journal:  PLoS One       Date:  2011-06-30       Impact factor: 3.240

6.  Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas.

Authors:  Walter Stummer; Herbert Stepp; Otmar D Wiestler; Uwe Pichlmeier
Journal:  Neurosurgery       Date:  2017-08-01       Impact factor: 4.654

7.  In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells.

Authors:  Rainer Ritz; Christian Scheidle; Susan Noell; Florian Roser; Martin Schenk; Klaus Dietz; Wolfgang S L Strauss
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.